Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
- The European generics market recorded revenues of $91.1 billion in 2023, representing a compound annual growth rate (CAGR) of 6.2% between 2018 and 2023.
- Market consumption volume increased with a CAGR of 1.8% between 2018 and 2023, to reach a total of 58.7% of total pharma volume in 2023.
- According to the publisher, in 2023, Germany, accounting for a share of 30.4% was the largest generics market in Europe. Factors such as accelerating healthcare costs, increasing abbreviated new drug application (ANDA) approvals, and a growing number of generic manufacturers supported the region’s generics market.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Europe
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts
Reasons to Buy
- What was the size of the Europe generics market by value in 2023?
- What will be the size of the Europe generics market in 2028?
- What factors are affecting the strength of competition in the Europe generics market?
- How has the market performed over the last five years?
- How large is Europe’s generics market in relation to its regional counterparts?
Table of Contents
1 Executive Summary
2 Market Overview
3 Market Data
4 Market Segmentation
5 Market Outlook
6 Five Forces Analysis
7 Competitive Landscape
8 Company Profiles
9 Macroeconomic Indicators
10 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Teva Pharmaceutical Industries Ltd
- Novartis AG
- Hikma Pharmaceuticals Plc
- Sanofi
- Sandoz Group AG
